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ABSTRACT
We aimed to assess and synthesize the information available in the literature regarding the treatment of American tegumentary 
leishmaniasis in special populations. We searched MEDLINE (via PubMed), EMBASE, LILACS, SciELO, Scopus, Cochrane 
Library and mRCT databases to identify clinical trials and observational studies that assessed the pharmacological treatment of 
the following groups of patients: pregnant women, nursing mothers, children, the elderly, individuals with chronic diseases and 
individuals with suppressed immune systems. The quality of evidence was assessed using the Grading of Recommendations, 
Assessment, Development and Evaluations (GRADE) approach. The available evidence suggests that the treatments of choice for 
each population or disease entity are as follows: nursing mothers and children (meglumine antimoniate or pentamidine), patients 
with renal disease (amphotericin B or miltefosine), patients with heart disease (amphotericin B, miltefosine or pentamidine), 
immunosuppressed patients (liposomal amphotericin), the elderly (meglumine antimoniate), pregnant women (amphotericin 
B) and patients with liver disease (no evidence available). The quality of evidence is low or very low for all groups. Accurate 
controlled studies are required to ﬁ ll in the gaps in evidence for treatment in special populations. Post-marketing surveillance 
programs could also collect relevant information to guide treatment decision-making.
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INTRODUCTION
Some patient populations present challenges for the 
treatment of American tegumentary leishmaniasis (ATL). These 
populations include pregnant women, nursing mothers, children, 
the elderly, individuals with chronic diseases and individuals 
with suppressed immune systems. These individuals are 
excluded from clinical trials1 to achieve homogeneous groups. 
As a result, the available evidence on the effectiveness and safety 
of treatments in special populations of patients is scarce2, which 
makes clinical decision-making difﬁ cult.
The therapeutic options available to treat ATL are limited, 
and the current evidence for recommendations on the 
treatment of cutaneous leishmaniasis (CL) is generally weak3-5. 
Pentavalent antimonials (SbV) have been the drugs of choice 
for more than six decades. However, they have high toxicity 
and are contraindicated in children, pregnant and breastfeeding 
women and chronically ill patients6-9. Pentamidine isethionate 
and amphotericin B are the second-line treatments7,9,10. In the 
last decade, miltefosine was introduced as an oral alternative11 
whose effectiveness for treating CL and mucosal leishmaniasis 
(ML) was shown in clinical trials conducted in Guatemala, 
Colombia, Bolivia and Brazil12-17.
The present study reports results found from a literature 
review of the treatment of ATL in special populations.
METHODS
Study type: this is a summary of evidence with systematic 
search, selection and data extraction processes.
Study eligibility criteria: clinical trials and observational 
studies were considered eligible if they assessed pharmacological 
treatment using the main drugs used in the treatment of ATL 
(meglumine antimoniate, amphotericin, pentamidine isethionate 
and miltefosine) in one of the following patient populations: 
pregnant women, nursing mothers, children (individuals under 
16 years of age), the elderly (individuals over 60 years or age) 
and individuals with renal disease, heart disease, liver disease 
or suppressed immune systems (e.g., individuals with human 
immunodeﬁ ciency virus (HIV) infection or individuals receiving 
therapy with immunosuppressive drugs or bone marrow or 
solid organ transplantation). For renal, heart and liver disease, 
we considered the same deﬁ nition that the included papers 
employed.
Studies regarding the treatment of diseases other than ATL, 
such as mycoses, were not considered eligible. However, when 
there was a lack of speciﬁ c studies for ATL in special groups, 
additional studies regarding visceral leishmaniasis (VL) or Old 
World CL were also assessed.
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LITERATURE SEARCH
In November 2010, a broad search was conducted by one 
of the authors (JSFS) in MEDLINE (via PubMed), EMBASE, 
LILACS, SciELO, Scopus, Cochrane Library and mRCT. 
There was no restriction on language or publication date. The 
search strategy included the following terms: leishmaniasis, 
cutaneous, mucocutaneous, pentamidine, amphotericin B, 
meglumine antimoniate, miltefosine, adverse effects, new 
world leishmaniasis, American leishmaniasis, side effects and 
undesirable effects. The last search update was performed on 
July 2013.
Secondary sources of information were also consulted: 
the Centers for Disease Control and Prevention (CDC), the 
Food and Drug Administration (FDA) and the World Health 
Organization (WHO)18-20.
Study selection and data extraction: one author selected 
the studies from the titles and abstracts (JSFS) and another 
conﬁ rmed the data (TFG). The same process was used to extract 
relevant information regarding anti-leishmanial drugs used in 
special populations.
Data analysis and critical appraisal: the studies were labeled 
as laboratory studies, case reports, case series, case-control 
studies, cohort studies, narrative reviews, systematic reviews or 
clinical trials and grouped according to the special population 
of patients studied: pregnant women, nursing mothers, children, 
the elderly, patients with chronic diseases and patients with 
suppressed immune systems.
Regarding the drugs used for treatment, the U.S. FDA 
Pregnancy Category Deﬁ nitions18 were used to rate the best 
pharmacotherapy option for pregnant women. To classify the 
risk for nursing mothers, we adopted the WHO Breastfeeding 
and Maternal Medication Recommendations for Drugs20, 
which consider ﬁ ve categories ranging from compatible with 
breastfeeding to avoid using.
After the eligible studies were selected, the evidence 
presented was rated based on the Grading of Recommendations, 
Assessment, Development and Evaluations (GRADE) 
approach21. No information produced by regulatory agencies 
was considered for the assessment of the quality of evidence.
RESULTS AND DISCUSSION
Ninety-seven references were found regarding therapeutic 
options for ATL treatment in pregnant women, nursing 
mothers, children, the elderly, and patients with renal disease, 
heart disease, liver disease or suppressed immune systems 
(Figure 1). Most of the included studies were case reports 
(Table 1). The special group with the highest number of 
publications was patients with suppressed immune systems. No 
description was found for anti-leishmaniasis therapy in nursing 
mothers. For children, six clinical trials were available. Although 
a clinical trial was found for the renal disease group, it was not 
considered for the treatment quality assessment because its 
purpose was the prevention of nephrotoxicity. The quality of 
the evidence was very low for most groups, including children 
(Table 2).
Pregnant women: only amphotericin B is acceptable for use 
during pregnancy according to the FDA18 (Table 3). Although 
the FDA pregnancy category provides guidance regarding a 
drug’s potential fetal risks, limitations such as a lack of a speciﬁ c 
toxic dose or predisposing pregnancy trimester complicate its 
application22. Amphotericin B can cross the placenta and reach 
low concentrations in the amniotic ﬂ uid23, but its safety in 
pregnant women was established in the treatment of systemic 
mycoses18. No studies were found assessing the effectiveness of 
amphotericin B in ATL treatment. In pregnant women with VL, 
amphotericin is preferred over other drugs24. Moreover, there 
were no adverse effects on the fetus or abortions when it was 
used for VL during the ﬁ rst or second trimester25,26.
Information regarding meglumine antimoniate safety in 
pregnancy is scarce27. Pentavalent antimonials are considered 
a category C drug by the FDA18 (Table 3). Experimental 
studies in pregnant rats showed an increase in fetal skeletal 
malformations, particularly in the atlas bone28. In addition, this 
drug may be toxic to the embryo even in the absence of signs 
of maternal toxicity29.
In humans, the evidence for meglumine antimonite treatment 
in pregnant women with ATL is limited. There are two case 
reports of patients using the drug in the ﬁ rst trimester. The drug 
was discontinued as soon as pregnancy was identiﬁ ed without 
harm to fetus, pregnant mother or labor30. Other studies report 
the treatment of 70 VL pregnant women with SbV. Among 
FIGURE 1 - Search results and selection of articles per special group. Note: The 
search on LILACS did not retrieve any results. References 61 and 62 were included 
for more than one group, what makes the total of included studies less than the 
sum of all studies by group. Numbers in superscript represent the references list.
Studies found through database search
(n = 1,340)
620 PubMed 151 Central
389 EMBASE 93 Scopus
74 mRCT 13 SciELO
Excluded articles
(n = 1,243)
Studies included in the review
(n = 97)
Renal disease
(n = 11 )9,60-68,70Pregnant






Elderly (n = 8)52-59
Immunosuppressed
(n = 42) 62,75-115Nursing mothers
(n = 0)
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TABLE 1 - Studies classiﬁ ed according to type by each special group reported in this review.
       Special populations
 pregnant nursing   the  renal heart liver immuno  
Study type women mother children elderly disease disease disease suppressed Total
Laboratory study* 427-29,37 NA 140 NA 167 NA 273,74 177 9
Case reports 324,30,31 NA 444,46-48 159 361,62,68 261,72 NA 3062,75,76,78,79,82-91, 42
Case series† 225,26 NA 145 354,57,58 - NA NA 381,99,102 9
Case-control study NA NA NA NA NA NA NA 180 1
Cohort study 232,38 NA 143 452,53,55,56 360,63,64 171 NA - 11
Narrative review‡ 622,23,33-36 NA 151 NA 170 NA NA 692,94,100,101,106,115 14
Systematic review NA NA - NA 29,65 19 19 1107 5
Clinical trial NA NA 616,17,41,42,49,50 NA 166§ NA NA 1104 8
Total 17 0 14 8 11 4 3 42|| -
*Laboratory experimental studies; †includes retrospective studies of series of patients treated (medical records); ‡ narrative review on the main 
therapeutic options available; § clinical trial on preventing amphotericin nephrotoxicity;  || one study 107presented a case report and a systematic 
review in the same manuscript; NA: not available. Numbers in superscript represent the references list.
TABLE 2 - Quality of evidence for American tegumentary leishmaniasis therapy in special groups (Adapted from GRADE). 
           Special groups
 pregnant  nursing  the renal heart liver immune
Drug woman mother children elderly disease disease disease suppressed
Meglumine antimoniate very low NA low very low NA very low very low very low
Pentamidine NA NA low NA NA NA NA very low
Amphotericin B very low NA very low NA very low NA NA very low
Liposomal amphotericin very low NA very low NA very low NA NA very low
Miltefosine very low NA low NA very low NA very low very low
NA: not available; GRADE: Grading of Recommendations, Assessment, Development and Evaluations.
these 70 women, there were 16 cases of abortion in the ﬁ rst or 
second trimester26,31,32.
Pentamidine isethionate should be avoided during 
pregnancy. The FDA category risk for this drug is C 
(Table 3) because the drug’s manufacturer did not conduct 
animal reproductive studies. In studies conducted after the drug 
was marketed, pentamidine was teratogenic but not embryocidal 
when administered to animals. Pentamidine may cross the 
human placenta18.
Miltefosine has exhibited teratogenicity and should therefore 
not be administered to pregnant women33-35. Studies in rats and 
rabbits have demonstrated embryotoxicity, fetotoxicity and 
teratogenicity28,29,36. Compulsory contraception is required for 
women of childbearing age who intend to use miltefosine37. 
Furthermore, as a precaution, conception should be delayed for 
236 to 4 months38 after treatment ends. There is no rating for the 
use of miltefosine during pregnancy because it is not registered 
by the FDA (Table 3).
Nursing mothers: according to the WHO, meglumine 
antimoniate and pentamidine isethionate are the only two drugs 
for ATL treatment that are compatible with breastfeeding20 
(Table 3). Data regarding the use of amphotericin B by 
breastfeeding women are lacking22.
The SbV concentration in breast milk is low (3.5mg Sb/ml), 
with little effect on the newborn39. The excretion of amphotericin 
B, pentamidine isethionate and miltefosine in breast milk is 
93-98,103,107-114
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TABLE 3 - Safety recommendations for drugs used for American 
tegumentary leishmaniasis treatment in pregnant women and nursing 
mothers.
Drug Pregnancy* Breastfeeding†
Meglumine antimoniate C CB
Amphotericin B B NA
Liposomal amphotericin B NA
Pentamidine C CB
Miltefosine NA‡ NA
*Index of drug toxicity criteria adopted by the FDA, United States 
of America18-20; †Index of Breastfeeding and Maternal Medication 
Recommendations for Drugs by World Health Organization18-20; 
‡ Although miltefosine is not registered by the FDA, its use is 
contraindicated in pregnancy; B: remote possibility of fetal harm; 
animal studies showed no risk to the fetus; there are no studies 
in humans; C: possible harm to the fetus; insufﬁ cient controlled 
studies in humans and animals; CB: compatible with breastfeeding; 
FDA: Food and Drug Administration. NA: not available.
unknown. Therefore, these drugs are not recommended in 
nursing mothers. No data are available regarding the risk to 
the child18 (Table 3).
Children: mMost studies found included children between 
2 and 12 years of age. According to the Brazilian health 
authorities, meglumine antimoniate is the drug of choice to treat 
pediatric patients39. The maximum daily dose of SbV for children 
under 12 years of age must not exceed 121.5mg (7.5ml), and 
treatment of children under 18 months is not recommended39. 
However, CL treatment with meglumine antimoniate is less 
effective in children than in adults40-42. The lower efﬁ cacy may 
result from the pathogenicity of the parasite or the particular 
immune response of this age group40,42. Meglumine antimoniate 
for the treatment of CL seems to reduce blood cell counts and liver 
enzymes more frequently in children than in adults and appears 
to signiﬁ cantly increase serum amylase and lipase levels43. 
A sickle cell crisis has been reported as an adverse effect of CL 
treatment with meglumine antimoniate in a 6-year-old child in 
Colombia44.
Intra-lesional meglumine antimoniate seems to be an 
alternative for children with CL. An infusion of the maximum 
dose of 10ml at intervals of 7 to 15 days proved to be more 
effective and better tolerated than conventional intramuscular 
treatment in this age group in Brazil45.
Scarce data are available for ATL treatment with amphotericin 
B in children. We found three case reports of children infected 
by Leishmania (Viannia) braziliensis treated with amphotericin 
deoxycholate whose CL lesions were cured without adverse 
effects46,47. In contrast, VL treatment with liposomal amphotericin 
showed no difference in efﬁ cacy or safety between children and 
adults18. In a double-blind study with pediatric patients (16 years 
of age or younger), liposomal amphotericin presented a lower 
incidence of hypokalemia, chills, vomiting and hypertension 
than amphotericin deoxycholate18.
Pentamidine treatment for CL is considered to represent 
an unlabeled use by the FDA18. The CDC recommended dose 
for children is 2 to 3mg/kg IM or IV on alternate days for 4-7 
doses19. In Brazil, a 14 year-old girl with CL was cured after 
pentamidine treatment48, and a recent randomized controlled 
trial (RCT) including children with CL showed similar efﬁ cacy 
of pentamidine and meglumine in the treatment of ATL49 caused 
by Leishmania (Viannia) guyanensis.
Oral administration and low toxicity favor the use of 
miltefosine in this age group50. There were two RCTs including 
children 2 to 12 years of age with CL in Brazil16,17 and one 
in Colombia50. The cure rate of miltefosine was non-inferior 
compared to meglumine antimoniate16,17,50. However, miltefosine 
was less effective for children infected by Leishmania 
guyanensis in Brazil17, possibly because of lower plasma 
concentrations of miltefosine in children51. The most frequently 
reported adverse event was vomiting (12/28 children; 43%)17.
The elderly: in the treatment of ATL, the patient’s age should be 
considered, as most adverse reactions occur in individuals over 50 
years of age52. Pentavalent antimonials are the most widely adopted 
drugs for CL treatment in elderly patients. However, there are no 
pharmacokinetics studies in this group. The incidence of CL in 
the population over 65 years of age is increasing signiﬁ cantly53. 
American tegumentary leishmaniasis patients between 60 and 92 
years of age were studied in Brazil. Of the 44 patients, 36 (82%) 
had CL, and eight (18%) had mucocutaneous leishmaniasis 
(MCL). Low-dose meglumine antimoniate was administered 
three times a day (5mg/kg/day) with complete resolution in 
33 (75%) cases. However, treatment was discontinued in 
nine (21%) subjects because of moderate to severe adverse effects, 
such as hypoglycemia, anemia, pancreatitis, increased transaminase 
levels, thrombocytopenia and renal failure54. Adverse events such 
as renal tubular dysfunction and hematological, heart and liver 
abnormalities are common causes of treatment interruption in this 
age group. Advanced age is one of the risk factors for tinnitus, which 
affects 5% of elderly patients using meglumine antimoniate53. 
Electrocardiogram abnormalities associated with meglumine 
antimoniate are more frequent in the elderly. Angiotensin-
converting enzyme inhibitors may have a cardioprotective effect in 
older patients using meglumine antimoniate55. Secondary infection 
was also observed more frequently in patients older than 45 years 
of age (p<0.04) subjected to meglumine antimoniate intralesional 
treatment for CL56. This is an effective and less toxic alternative 
treatment for CL patients with contraindications to systemic 
therapy57. Cutaneous leishmaniasis patients younger than 65 years 
of age without co-morbidities can be safely and effectively treated in 
specialist centers with parenteral SbV without hospital admission58.
No studies were found for ATL treatment with amphotericin 
in the elderly. However, it was not necessary to change the 
standard dose of liposomal amphotericin in elderly patients 
treated for other diseases. Careful monitoring is recommended18.
There were also no studies for ATL treatment with 
pentamidine in elderly patients. A 64-year-old woman who 
developed severe hypokalemia under meglumine antimoniate 
treatment for Old World ML was successfully treated with 
miltefosine59.
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Patients with kidney disease: pentavalent antimonials are 
contraindicated for ATL treatment in patients with severe 
renal impairment. Renal evaluation studies are rare in ATL. 
Urinary concentration and acidiﬁ cation defects were found in a 
signiﬁ cant number of patients treated with SbV60. These drugs 
should therefore be used with caution in patients with any renal 
dysfunction. A patient with previous renal problems presenting 
with MCL was submitted to a course of prednisolone combined 
with the SbV treatment and had a good response to treatment. 
Adjuvant glucocorticoid therapy provided symptomatic relief61.
Liposomal amphotericin may represent a safe, efﬁ cient and less 
toxic alternative therapy for ATL; it was safely used in a patient 
with kidney failure and diabetes mellitus who was on dialysis. 
Healing of CL lesions was achieved with a total dose of 600mg62 
even though amphotericin B is associated with dose-dependent 
nephrotoxicity, particularly when the daily dose is greater than 
35mg. Risk factors that predispose patients to this condition are 
as follows: body weight over 90kg, concomitant cyclosporine or 
aminoglycoside usage, chronic renal failure (CRF)63, male sex, 
advanced age and jaundice64. Patients with more than two risk 
factors for nephrotoxicity are potential candidates for alternative 
therapy63. Amphotericin B delivered as a locally prepared lipid 
emulsion or in liposomes may reduce nephrotoxicity65.
A randomized controlled trial conducted in Peru with 
MCL patients66 showed that hydration with oral hyperosmolar 
solution was as effective as parenteral hydration to prevent 
glomerular injury caused by amphotericin B. Laboratory 
studies indicate that hypokalemia predisposes patients to tubular 
damage from amphotericin B67.
Pentamidine is contraindicated in patients with CRF. This 
drug has slow excretion from the body and can accumulate in 
the kidneys and liver. Thus, pentamidine must be used with 
caution in patients with renal dysfunction18.
Miltefosine may be an alternative for ATL treatment in 
patients with renal impairment. There is a case report of CL 
in an elderly patient with CRF who was treated with 1.8mg/
kg/day of miltefosine for 28 days. The patient’s skin lesions 
healed and no adverse events were reported68. However, 1% 
of miltefosine patients may develop nephrotoxicity69. Mild to 
moderate increases in creatinine are an adverse effect related 
to miltefosine9. Therefore, renal function should be monitored.
A recent literature review on renal involvement in VL 
suggests that SbV, amphotericin B, pentamidine, miltefosine, 
paromomycin and sitamaquine may be associated with a high 
risk of renal toxicity70.
Patients with heart disease: meglumine antimoniate 
is contraindicated in patients with heart disease39, and it is 
associated with arrhythmias and conduction disorders in adults 
with no previous heart disease71. Electrocardiographic QTc 
interval prolongations are an adverse effect related to SbV9,61. 
However, these changes are usually reversible after drug 
discontinuation. A case of pericarditis was reported in a CL 
patient treated with systemic meglumine antimoniate72. 
Amphotericin B is also associated with the occurrence of 
arrhythmias. Therefore, its use for ATL treatment in cardiac 
patients requires close monitoring. Rapid infusions should be 
avoided to prevent arrhythmias and local irritation18.
Pentamidine should be used with caution in patients with 
preexisting heart disease. Hypotension, hypertension and 
arrhythmia, including ventricular tachycardia, have been 
reported. Pentamidine is known to prolong the QT interval 
and subsequently increases the risk of occurrence of torsade 
de pointes18.
We could not ﬁ nd a description in the medical literature 
of cardiac adverse events during ATL treatment with 
miltefosine13,14,16,17.
Patients with liver disease: there are no studies of ATL 
treatment with meglumine antimoniate in patients with liver 
impairment. Meglumine antimoniate is contraindicated in 
patients with severe liver disease. Mild to moderate increases 
in liver and pancreatic enzyme levels are adverse effects related 
to SbV9. Case reports of hepatitis arising from its use have 
been described. Therefore, another drug is recommended for 
treatment18.
The pharmacokinetics of liposomal amphotericin were not 
studied in patients with chronic liver disease73.
Pentamidine should be used with caution in patients with 
liver dysfunction18.
The clearance of miltefosine is performed by hepatocyte 
phospholipases74, and 1% of patients using it may develop 
hepatotoxicity69. Mild to moderate increases in aminotransferase 
levels were adverse effects related to miltefosine9. Therefore, 
laboratory monitoring of liver function is recommended. 
Patients with suppressed immune systems: ATL infection 
is emerging as a result of immunosuppression, and HIV is 
the most common cause62,75-88. Bone marrow or solid organ 
transplantation89-95 and therapy with immunosuppressive or biologic 
drugs96-98 also have been associated with the appearance of ATL. 
In immunosuppressed patients, CL is characterized by atypical 
cutaneous lesions and persistent negativity of diagnostic tests91.
Human immunodeﬁ ciency virus/acquired immunodeﬁ ciency 
syndrome: the association between ATL and HIV-AIDS has 
increasingly been described in many regions of the world99 
together with immune reconstitution inﬂ ammatory syndrome 
presentation82,84,85,100. 
The evidence for the treatment of co-infection with HIV 
and LC is still very limited101. Generally, systemic therapy is 
used to prevent the spread of the parasite. The same approach 
used for immunocompetent individuals is applied with weekly 
monitoring39. Recurrences are frequent80,86 and fatal cases have 
been reported86. A series of 15 patients with ATL/HIV-AIDS 
association in Brazil was recently published, where only 
seven patients were successfully treated at the ﬁ rst attempt99. 
Leishmaniasis was the ﬁ rst opportunistic infection in 60% 
of patients in another case series of 23 HIV patients recently 
investigated in Brazil. The cluster of differentiation antigen 4 
(CD4)+ T-cell count was below 200 cells/mm in 80% of cases 
and did not increase after clinical remission despite antiretroviral 
therapy. The ﬁ rst drug chosen to treat the cases was SbV, but 
the therapeutic regimen was altered to amphotericin B in 12 
of 17 cases because of side effects. Relapses were reported in 
56% of the patients102.
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An HIV-positive patient with MCL caused by L. braziliensis 
was treated successfully with a short course of meglumine 
antimoniate75. However, SbV showed no therapeutic response 
in four LM co-infected patients. Cardiotoxicity occurred in three 
cases. Pentamidine and amphotericin were more effective78. 
Pentamidine was used to treat HIV-infected patients with CL 
caused by L. guyanensis in a case-control study in French Guiana. 
HIV patients had a higher rate of recurrence or reinfection and a 
lower rate of recovery after pentamidine treatment80.
In Bolivia, amphotericin deoxycholate was used for 80 days 
to treat HIV-infected patients with CL caused by L. braziliensis 
without success87. However, liposomal amphotericin showed 
a good response in two cases of co-infected MCL and HIV 
patients who had not responded to meglumine antimoniate76,103. 
In addition, liposomal amphotericin was also used successfully 
in co-infected CL and HIV patients with a 1,500mg dose62.
Patients co-infected with HIV and ATL have been treated with 
miltefosine with initial success, but then relapsed104,105. However, 
Old World CL patients with HIV were cured with miltefosine after 
treatment failure with conventional amphotericin B, liposomal 
amphotericin and sodium stibogluconate81,83. An experimental 
study in immunosuppressed rats suggests that miltefosine may 
be useful in both the acute and maintenance phases77.
Other types of immune system suppression - There were no 
studies of ATL treatment in patients with other types of immune 
system suppression. However, treatment of patients with VL 
and Old World CL has been reported. In transplant recipients, 
CL and ML are rare and usually there is a time interval between 
transplantation and disease manifestation106. Reviews of organ 
transplant recipients with leishmaniasis show that the majority 
of patients have undergone renal transplantation, and most cases 
are identiﬁ ed as visceral-type disease93,107-109.
Patients presenting LV after organ transplantation treated 
with SbV presented with amylase and lipase elevation in 
addition to pancreatitis110. In contrast, a CL case treated with 
intralesional injections of meglumine antimonate was reported 
after 20 months of infliximab treatment for ankylosing 
spondylitis (uveitis and arthritis). Inﬂ iximab was discontinued, 
and local treatment led to rapid improvement111.
An 83-year-old patient with myelodysplastic syndrome 
was treated successfully with liposomal amphotericin for CL 
caused by Leishmania major without adverse effects112. Renal 
transplantation patients presenting with VL also had a good 
response to liposomal amphotericin110,113. However, toxicity 
occurred in patients with LV after heart transplantation, and 
treatment needed to be interrupted114. 
Use of pentamidine or miltefosine has not been reported in 
other populations of immunosuppressed patients115. 
In conclusion, a summary of the more apropriate ATL 
therapeutic options for each special population reviewed in 
this paper is shown in Table 4. A common ﬁ nding in all groups 
is the low or very low quality of evidence. There is a need 
for controlled studies of higher quality, ideally randomized 
controlled trials. Post-marketing surveillance programs could 
play a role in ﬁ lling the existing gaps in knowledge.
TABLE 4 - Summary of the proper American tegumentary leishmaniasis treatment options reviewed for each special population. 
Special populations Drug of choice Evidence level
Pregnant women amphotericin B very low
Nursing mother NA† NA
Children meglumine antimoniate or miltefosine for Leishmania braziliensis;  low
 meglumine antimoniate or pentamidine for Leishmania guyanensis
The elderly meglumine antimoniate  very low
 (low dose or intralesional injections)*
Renal disease amphotericin B or miltefosine very low
Heart disease amphotericin B or pentamidine or miltefosine (used with caution)18-20 very low
Liver disease NA NA
Immunosuppressed patients liposomal amphotericin very low
NA: not available. †: according to the World Health Organization, the drugs for American tegumentary leishmaniasis treatment that are compatible 
with breastfeeding are meglumine antimoniate and pentamidine isethionate20. This evidence however, was not found in clinical trials and 
observational studies, the study design that was eligible for inclusion in this review. *To avoid toxicity or when systemic therapy is contraindicated.
The authors declare that there is no conﬂ ict of interest.
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